1. Nakayama H, Jorgensen HS, Raaschou HO, Olsen TS. Recovery of upper extremity function in stroke patients: the Copenhagen stroke study. Arch Phys Med Rehab 1994;75:394-398.

2. Rousseaux M, Kozlowski O, Froger J. Efficacy of botulinum toxin in upper limb function of hemiplegic patients. J Neurol 2002;249:76-84.

3. Bergfeldt U, Borg K, Kullander K, Julin P. Focal spasticity therapy with botulinum toxin: effects on function, activities of daily living and pain in 100 adult patients. J Rehabil Med 2006;38:166-171.

4. Cardoso E, Pedreira G, Prazeres A, Ribeiro N, Melo A. Does Botulinum toxin improve the Function of the patient with spasticity after stroke? Arq Neuropsiquiatr 2007;65:592-595.

5. Sampaio C, Ferreira JJ, Pinto AA, Crespo M, Ferro JM, Castro-Caldas A. Botulinum toxin type A for the treatment of arm and hand spasticity in stroke patients. Clin Rehabil 1997;11:3–7

6. Gallichio JE. Pharmacologic management of spasticity following stroke. Phys Ther 2004;84:973–981

7. Cardoso E, Rodrigues B, Lucena R, Oliveira IR, Pedreira G, Melo A. Botulinum toxin type A for the treatment of the upper limb spasticity alter stroke: a meta-analysis. Arq Neuropsiquiatr 2005;63:30-33.

8. Ward A, Roberts G, Warner J, Gillard S. Cost-effectiveness of botulinum toxin type a in the treatment of post-stroke spasticity. J Rehabil Med 2005;37:252–257.

9. Simpson DM, Alexander DN, O’Brien CF, Tagliati M, Asbbad AS, Leon JM, et al. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology 1996;46:1306-1310.

10. Ozcakir S, Sivrioglu, K. Botulinum Toxin in Poststroke Spasticity. Clin Med Res 2007; 5:132 -138

11. Rosales RL, Chua-Yap AS. Evidence-based systematic review on the efficacy and safety of botulinum toxin-A therapy in post-stroke spasticity. J Neural Transm. 2008;115:617-623.

12. Snow BJ, Tsui JK, Bhatt MH, Varelas M, Hashimoto SA, double-blind study. Ann Neurol 1990;28:512-615.

13. Das TK, Park DM. Effect of treatment with Botulinum toxin on spasticity Postgrad Med J 1989;65:208-210.

14. Hesse S, Krajnik J. Luecke D, Jahnke MT, Gregoric M, Muritz KH. Ankei muscle activity before and after botulinum toxin therapy for lower limb extensor spasticity in chronic hemiparetic patients. Stroke 1996; 27: 455-460.

15. Hesse S, Lucke D, Mlezic M, Bertelt C, Friedrich H, Gregoric M, et al. Botulinum toxin treatmen for lower limb extensor spasticity in chronic hemiparetic patients. J Neurol Neurosurg Psychiatry. 1994; 57: 1321-1324.

16. Marco E, Duarte E, Vila J, Tejero M, Guillen A, Boza R, Escalada F, Espadaler JM. Is botulinum toxin type A effective in the treatment of spastic shoulder pain in patients after stroke? A double-blind randomized clinical trial. J Rehabil Med. 2007;39:440-447.

17. Brashear A, Gordon MF, Elovic E, Kassicieh VD, Marciniak C., Do M, et al. Intra-muscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med. 2002; 347: 395-400

18. Sheean G. Botulinum toxin treatment of adult spasticity: a benefit-risk assessment. Drug Saf 2006;29:31-48.

19. Bakheit AM. Optimising the methods of evaluation of the effectivess of botulinum toxin treatment of post-stroke muscle spasticity. J Neurol Neurosurg Psychiatry. 2004;75:665-666.

20. Sepulveda A, Salinas P, Monzón de Briceño Y, Castillo Trujillo D. Manejo de espasticidad en miembros superiores con infiltraciones de fenol y toxina botulínica. MedULA. 2003. 12(1-4). Disponible en: http://www.saber.ula.ve.

21. Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner 1964; 192:540-542.

22. Granger CV, Hamilton BB. The Functional Independence Measure. In: Mc Dowel I, Newel C. Measuring Health: A Guide to Rating Scales and Questions. Second Ed. New York: Oxford University. 1987.

23. Hill J. Áreas de ejecución en terapia ocupacional. 8ª ed. Madrid: Editorial Médica Panamericana, 2001.

24. Paolinelli GC, González HP, Doniez SME, Donoso DT, Salinas RV. Instrumento de evaluación funcional de la discapacidad en rehabilitación: Estudio de confiabilidad y experiencia clínica con el uso del Functional Independence Measure. Rev Méd Chile, 2001; 129: 23-31.

25. Brin MF. Dosing, administration, and a treatment algorithm for use of botulinum toxin A for adult-onset spasticity. Spasticity Study Group. Muscle Nerve Suppl. 1997;6:S208-S220.

26. Ward A, Aguilar M, De Beyl Z, Gedin S, Kanovsky P, Molteni F, et al. Use of botulinum toxin type A in management of adult spasticity. A European consensus statement. J Rehabil Med. 2002;35:1-2.

27. Abu-Zeid HA, Choi NW, Nelson NA. Epidemiologic features of cerebrovascular disease in Manitoba: incidence by age, sex and residence, with etiologic implications. Can Med Assoc J. 1975; 113: 379–384.

28. Cruz Franco HM, Del Brutto OH. Subtipos de Enfermedad Cerebrovascular: Análisis del registro de la Unidad de Ictus del Hospital Clínica Kennedy. Rev Ecuator Neurol. 2007; 16(2). Disponible en: http://www.medicosecuador.com/revecuatneurol.

29. Cabrera Rayo A, Martínez Olazo O, Laguna Hernández G, Juárez Ocaña R, Rosas Barrientos V, Loria Castellanos J, et al. Epidemiología de la enfermedad vascular cerebral en hospitales de la Ciudad de México. Estudio multicéntrico. Med Int Mex. 2008;24:98-103.

30. Simpson DM, Gracies JM, Yablon SA, Barbano R, Brashear A, the BoNT/TZD Study Team. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo-controlled study. J Neurol Neurosurg Psychiatry. 2009; 80:380-385.

31. Rampazo FM, Bianchin MA, Oliveira FN, Lucato Jr RV. Análisis comparativo de los beneficios de la ergoterapia en pacientes espásticos con afectación de las manos antes y después de la infiltración de toxina botulínica. Rev Neurol. 2009; 48:459-462.

32. Foulkes MA, Wolf PA, Price TR, Mohr JP, Hier DB. The Stroke Data Bank: design, methods, and baseline characteristics. Stroke. 1988; 19;547-554.

33. Slawek J, Bogucki A, Reclawowicz D. Botulinum toxin type A for upper limb spasticity following stroke: an open-label study with individualized, flexible injection regimens. Neurol Sci. 2005; 26:32-39.

34. Mayer NH. Clinic physiologic concepts of spasticity and motor dysfunction in adults with an upper motoneuron lesion. Muscle Nerve. 1997; 20(suppl 6):S1-S13.

35. Esquenazi A, Mayer N. Botulinum toxin for the management of muscle over activity and spasticity after stroke. Curr Atheroscler Rep. 2001; 3:295298.

36. Miscio G, Del Conte C, Pianca D, Colombo R, Panizza M, Schieppati M, et al. Botulinum toxin in post-stroke patients: stiffness modifications and clinical implications. J Neurol. 2004; 251:189-196.

37. Sun SF, Hsu CW, Sun HP, Hwang CW, Yang CL, Wang JL. Combined botulinum toxin type A with modified constraint-induced movement therapy for chronic stroke patients with upper extremity spasticity: a randomized controlled study. Neurorehabil Neural Repair. 2010; 24:34-41.

38. Elovic EP, Brashear A, Kaelin D, Liu J, Millis SR, Barron R, et al. Repeated treatments with botulinum toxin type a produce sustained decreases in the limitations associated with focal upper-limb poststroke spasticity for caregivers and patients. Arch Phys Med Rehabil. 2008; 89:799-806.